Tavapadon significantly improves motor function and activities of daily living in adults with early Parkinson disease compared with placebo.

The FDA has updated the label for Caplyta to include phase 3 data showing a significant reduction in schizophrenia relapse risk.

Women with a higher number of live births appear to have a lower risk for stroke later in life, compared with no live births.

More severe atopic dermatitis increases the risk for sleep and memory disturbances among adults with atopic dermatitis.

Could you summarize the core thesis of your research regarding the ‘Cerebral Windkessel’ and how it redefines our ...

Stephen Sayle, a former tobacco industry executive, will be deputy director for legislative affairs at the CDC.

Deep learning algorithms effectively detect chronic optic neuritis atrophy patterns, but no models currently exist for acute phase diagnosis.

Virtual new patient neurology visits offer similar downstream utilization compared with in-person neurology visits.

Cognitive impairment and cognitive status can contribute to worse outcomes among patients with chronic kidney disease.

Eptinezumab plus education reduces monthly migraine days in adults with chronic migraine and medication-overuse headache.

FDA issues a Complete Response Letter to Grace Therapeutics for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.